3 Result: Inventiva
Inventiva: Promising Lanifibranor Trial Data; Bullish View Towards 89bio, BRP, CompoSecure
June 13th, 2023
Inventiva S.A. (Nasdaq: IVA), a pharmaceutical company, has announced encouraging results from a Phase II clinical trial evaluating lanifibranor in patients with nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus (T2D). Th. Read more
Akebia Therapeutics, MDxHealth, Avis Budget, argenx, Five9, Inventiva: Analyst Upgrades and Initiations Point to Potential Upsides
May 31st, 2023
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company, received an upgrade from Neutral to Overweight by Piper Sandler, with the price target raised from $2 to $4. On Wednesday, $AKBA closed at $1.04, indicating a potential u. Read more
Upgraded Rating for The Gap, First Commonwealth Financial, Wendy's, MaxLinear, and Inventiva
May 20th, 2023
The Gap, Inc. (NYSE: GPS) received an upgrade from Sell to Neutral by Citigroup, a notable financial institution. This upgrade suggests a shift in sentiment towards the company. On Friday, $GPS closed at $7.78, experiencing a decline of $0.33 (-4.07%. Read more
Want To Find Some News?
News By Industries
Recent Post
-
NJCP National Football Conference Names David Dalton Head Coach of Salt Lake Yeti
February 06th, 2026FDA Takes New Approach to "No Artificial Colors" Claims
February 06th, 2026NJCP National Football Conference Announces Micah Deckart as Head Coach of the Idaho Outlaws
February 05th, 2026
Member Login